Oncolytic vaccinia virus therapy of salivary gland carcinoma

JAMA Otolaryngol Head Neck Surg. 2013 Feb;139(2):173-82. doi: 10.1001/jamaoto.2013.1360.


Objective: To examine the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) against a panel of 5 human salivary gland carcinoma cell lines.

Design: The susceptibility of 5 salivary gland carcinoma cell lines to infection and oncolysis by GLV-1h68 was assessed in vitro and in vivo.

Results: All 5 cell lines were susceptible to viral infection, transgene expression, and cytotoxic reactions. Three cell lines were exquisitely sensitive to infection by very low doses of GLV-1h68. Orthotopic parotid tumors exhibited more aggressive behavior compared with flank tumors. A single intratumoral injection of GLV-1h68 induced significant tumor regression without observed toxic effects in flank and parotid tumor models; controls demonstrated rapid tumor progression.

Conclusion: These promising results demonstrate significant oncolytic activity by an attenuated vaccinia virus for infecting and lysing salivary gland carcinomas, supporting future clinical trials.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Animals
  • Carcinoma, Mucoepidermoid / pathology
  • Carcinoma, Mucoepidermoid / therapy*
  • Cell Line, Tumor
  • Gene Expression
  • Humans
  • Injections
  • Luciferases / genetics
  • Mice
  • Mice, Nude
  • Oncolytic Virotherapy*
  • Salivary Gland Neoplasms / pathology
  • Salivary Gland Neoplasms / therapy*
  • Vaccinia virus / genetics
  • Vaccinia virus / physiology*
  • Virus Replication
  • Xenograft Model Antitumor Assays
  • beta-Galactosidase / genetics


  • Luciferases
  • beta-Galactosidase